Introduction
============

Type 2 diabetes mellitus (T2DM) represents a significant global health problem. It is estimated that six people die every minute from the disease worldwide, a figure that will soon make T2DM one of the world's most prevalent causes of preventable mortality.[@b1-dmso-3-173] The incidence of disease increases with age, obesity, physical inactivity, unhealthy diet, and ethnicity (Hispanics, Africans, and Aboriginals) and the rates are increasing among children.[@b2-dmso-3-173],[@b3-dmso-3-173] T2DM is caused by impaired glucose tolerance (IGT) as a result of insulin resistance and consequential islet β-cell exhaustion, with ensuing insulin deficiency impacting skeletal muscle, liver and adipose tissues.[@b4-dmso-3-173] In individuals with IGT, numerous genetic, host-related, and environmental factors contribute to the progression of insulin resistance to T2DM.[@b5-dmso-3-173]--[@b9-dmso-3-173] Obesity, however, is a major cause of insulin resistance[@b7-dmso-3-173] and can be complicated by metabolic dysregulation including hypertension and dyslipidemia (known collectively as the metabolic syndrome) which is a precursor of T2DM. The dyslipidemia involves high levels of triacylglycerides and circulating fatty acids originating from the diet or accelerated lipolysis in adipocytes. Direct exposure of muscle cells to these fatty acids impairs insulin-mediated glucose uptake and, therefore, may contribute to insulin resistance.[@b10-dmso-3-173],[@b11-dmso-3-173]

Within the last decade, a hypothesis was proposed to explain the pathogenesis of T2DM that connects the disease to a state of subclinical chronic inflammation.[@b12-dmso-3-173],[@b13-dmso-3-173] Inflammation is a short-term adaptive response of the body elicited as a principle component of tissue repair to deal with injuries and microbial infections (eg, cold, flu, etc.). It can be also elevated in chronic conditions such as peripheral neuropathy, chronic kidney disease and fatty liver. While the influence of fats is well known (see below), current thinking suggests that abnormal levels of chemokines released by the expanding adipose tissue in obesity activate monocytes and increase the secretion of pro-inflammatory adipokines. Such cytokines in turn enhance insulin resistance in adipose and other tissues, thereby increasing the risk for T2DM.[@b14-dmso-3-173],[@b15-dmso-3-173] Together, lipid toxicity and low-grade inflammation appear to be major assaults on insulin sensitivity in insulin-responding tissues.[@b11-dmso-3-173],[@b16-dmso-3-173],[@b17-dmso-3-173]

Activation of innate immunity promotes various inflammatory reactions that provide the first line of defense the body invokes against microbial, chemical, and physical injury, leading to repair of damage, isolation of microbial infectious threats and restoration of tissue homeostasis.[@b18-dmso-3-173],[@b19-dmso-3-173] Inherited variations in the degree of innate immune response may determine the lifetime risk of diseases upon exposure to adverse environmental stimuli.[@b20-dmso-3-173] Therefore, innate immune responses can be viewed as the outcome of interaction between genetic endowment and the environment.[@b21-dmso-3-173] The systemic reaction of innate immunity, known as the 'acutephase response', follows exposure to an exogenous insult (such as a pathogen or dietary factor) which triggers the release of pro-inflammatory cytokines like tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6.[@b22-dmso-3-173] These cytokines are derived primarily from macrophages and can directly enhance insulin resistance in adipocytes, muscle and liver cells.[@b11-dmso-3-173],[@b17-dmso-3-173] Macrophages infiltrate the expanding adipose tissue in obesity to remove dying cells and contribute to tissue angiogenesis.[@b23-dmso-3-173] The adipose tissue of obese rodents and humans is indeed excessively infiltrated by macrophages and dendritic cells.[@b11-dmso-3-173] Subsequent activation of macrophages towards an inflammatory phenotype results in cytokine synthesis and release.[@b24-dmso-3-173],[@b25-dmso-3-173] Cytokines then downregulate major anabolic cascades involved in insulin signaling and mediate adipocyte insulin resistance.[@b24-dmso-3-173],[@b25-dmso-3-173] Ultimately, this contributes to disruption of whole-body insulin sensitivity and impairs glucose homeostasis.[@b26-dmso-3-173]

In addition to their effect on insulin resistance, cytokines also act on the liver to increase the production of very-low density lipoproteins (VLDL), leading to the characteristic diabetic dyslipidemia,[@b27-dmso-3-173] and to stimulate the hepatic production of fibrinogen, an atherosclerotic risk factor.[@b12-dmso-3-173] Furthermore, cytokines deactivate the liver X receptors (LXR), resulting in an increased rate of cholesterol accumulation,[@b28-dmso-3-173] and ultimately trigger the hepatic production and secretion of acute-phase proteins such as C-reactive protein (CRP), plasminogen activator inhibitor-1 (PAI-1), serum amyloid-A, α1-acid glycoprotein, and haptoglobin (collectively known as inflammatory factors or markers) into the circulation. The synthesis of acute-phase reactants following the cytokine release characterizes the pre-clinical (or early) stages of T2DM[@b21-dmso-3-173] and exhibits graded increases as the disease progresses and clinical complications ensue[@b12-dmso-3-173] (see below).

Extensive experimental, clinical and epidemiological studies have linked obesity causally to the activation of inflammatory signaling pathways and to the subsequent manifestations of T2DM.[@b7-dmso-3-173],[@b29-dmso-3-173],[@b30-dmso-3-173] This relationship may facilitate the development of preventive measures for the disease at the early stages, as well as its main antecedent, obesity. For example, pharmaceutical and nutritional factors that reduce inflammation and the ensuing acute-phase reactant responses could be employed to improve insulin sensitivity and delay disease onset.[@b31-dmso-3-173]--[@b33-dmso-3-173] Furthermore, a subset of the pro-inflammatory cytokines and inflammatory factors may provide a phenotypic profile that can be utilized as a sensitive and specific composite biomarker for early detection of risk to T2DM. Taken together, these approaches may aid in reducing the rising rates of disease incidence and better address issues related to prevention and treatment.

This review was undertaken to examine current knowledge linking inflammatory signaling pathways within the innate immune system to the risk of T2DM. The possibility that inflammatory markers could serve as molecular targets for prevention and/or biomarkers for early risk prediction of T2DM is evaluated in the context of enhancing public health strategies for diabetes prevention and control.

Obesity, T2DM, and inflammation: Molecular mechanism(s) of association
----------------------------------------------------------------------

In obese people, insulin resistance is linked to the increased release of adipocyte-derived bioactive metabolites (ADBMs) such as lipids, free fatty acids, monocyte chemoattractant protein- 1 (MCP-1), and pro-inflammatory cytokines.[@b30-dmso-3-173] It should be emphasized, however, that although obesity is viewed as a predisposing factor to insulin resistance, other factors may also contribute. A study of young, insulin- resistant, lean offspring of patients with T2DM and insulin-sensitive controls of similar body mass index (BMI) showed similar plasma concentrations of TNF-α, IL-6, and adiponectin between the insulin-resistant and insulin-sensitive groups.[@b34-dmso-3-173] This suggests that in lean people, systemic inflammation may not play a significant role in the development of insulin resistance. In this case, proposed mechanisms for insulin resistance might then be attributed to a dysregulation of intramyocellular fatty acid metabolism.[@b14-dmso-3-173] In the liver this would also include an altered expression of transcription factor 6-α (ATF6) which controls expression of gluconeogenic genes.[@b35-dmso-3-173] Genetic predisposition also may contribute to the development of T2DM. Genome-wide association (GWA) and candidate gene studies over the past few years have so far uncovered 19 genes associated with T2DM.[@b36-dmso-3-173] The disease-related genetic variants identified have high frequencies in the populations assessed although their individual contributions to increases in risk of T2DM are modest. Ongoing GWAs that target lowfrequency genetic variants and assess copy number variants (CNVs) in addition to single nucleotide polymorphisms (SNPs) are likely to identify additional loci associated with T2DM risk, and some of these may play a significant role in the risk of disease development.[@b36-dmso-3-173] In lean subjects with T2DM, the dysregulation of fatty acid metabolism, the abnormal expression of gluconeogenic genes and the genetic predisposition necessitate the development of an additional set of biomarkers that target this subpopulation and relate to these risk factors.

In the obesity-related insulin resistance, once adipocytes are activated (ie, accumulate fat and exhibit caloric excess), they release abnormal levels of ADBMs, leading to the recruitment of monocytes within adipose tissues.[@b30-dmso-3-173] Monocyte differentiation into the macrophages lineage results in additional increases in the release of inflammatory factors and chemokines, propagating inflammatory responses both locally within adipose tissue and systemically elsewhere.[@b14-dmso-3-173],[@b17-dmso-3-173],[@b30-dmso-3-173] In both human[@b37-dmso-3-173] and animal[@b16-dmso-3-173] models, *TNF-α* gene expression is upregulated in adipose tissues during obesity, linking pro-inflammatory substances released from adipose tissues to insulin resistance in T2DM.

The role for pro-inflammatory cytokines in regulating insulin action and glucose homeostasis and their function in T2DM has been suggested by several lines of evidence. For example, compared to healthy individuals, subjects with T2DM risk factors such as obesity, hyper-triglyceridemia, or low high-density lipoprotein (HDL)-cholesterol exhibit higher serum levels of pro-inflammatory cytokines and acute-phase reactants than those who are not so predisposed.[@b13-dmso-3-173] Cytokines also show a gradual increase as the disease progresses to its complications.[@b13-dmso-3-173] Additionally, numerous prospective trials demonstrate that initial high levels of pro-inflammatory factors are associated with the manifestations of the disease.[@b38-dmso-3-173]--[@b43-dmso-3-173] Baseline circulating concentrations of IL-6, PAI-1, CRP, and fibrinogen were significantly higher in healthy subjects who became diabetic later in life (ie, after 4--10 years) compared to those who did not develop the disease.[@b38-dmso-3-173]--[@b43-dmso-3-173] Furthermore, exogenous administration of TNF-α or IL-6 results in insulin resistance,[@b16-dmso-3-173],[@b17-dmso-3-173],[@b37-dmso-3-173] whereas low serum levels of cytokine in knock-out mice[@b17-dmso-3-173],[@b44-dmso-3-173] or treatment with anti-TNF-α agents,[@b31-dmso-3-173] improved insulin sensitivity and glucose homeostasis. However, TNF-α is unlikely to be the only culprit for inducing insulin resistance and indeed many cytokines may act in synchrony to elicit the condition. Taken together, these observations suggest that inflammation is a feature when IGT develops at the pre-clinical stages of T2DM, perhaps at the overweight or obesity (see below).

The mechanisms that govern the association between the increased synthesis of inflammatory factors and T2DM are still being elucidated. In macrophages, adipocytes, antigen-presenting B-cells, dendritic cells, and Kupffer cells in the liver, a number of germline-encoded pattern recognition receptors (PRRs), such as the toll-like receptors (TLR), are activated upon ligand binding with conserved structural motifs that are either specific patterns of microbial components (eg, bacterial lipopolysaccharide \[LPS\])[@b45-dmso-3-173] or nutritional factors (eg, free fatty acids \[FFAs\]).[@b11-dmso-3-173],[@b18-dmso-3-173],[@b46-dmso-3-173]--[@b48-dmso-3-173] Binding to PRRs gives rise to inflammatory responses by mediating downstream transcriptional events that activate nuclear factor-κB (NFκB) and activator protein-1 (AP-1) and their pathways (see [Figure 1](#f1-dmso-3-173){ref-type="fig"}).[@b19-dmso-3-173] Upon activation, these intracytoplasmic molecular cascades upregulate the transcription of pro-inflammatory cytokine genes[@b22-dmso-3-173] and, consequently, the synthesis of acute-phase inflammatory mediators[@b49-dmso-3-173]--[@b51-dmso-3-173] and activation of c-Jun N-terminal kinase (JNK) and inhibitor of NFκB kinase-β (IKK). In liver and adipose tissue, these two molecules can inactivate the first target of the insulin receptor (INSR), IRS-1, thereby reducing downstream signaling towards metabolic outcomes.[@b52-dmso-3-173],[@b53-dmso-3-173] The interrelationship between these molecular targets suggests the expression and action of PRRs are the primary effector molecules in a downstream cascade that initiate dysregulation of insulin homeostasis. Therefore, altered expression/action, eg, as a result of SNP, in these PRRs may be employed to predict the possible development of T2DM (or earlier predisposing conditions) upon exposure to high levels of their ligands.

In addition to the activation of inflammation signals, strong evidence supports a direct role of FFAs in promoting insulin resistance. This has been ascribed to actions of their intracellular metabolites, primarily ceramide and diacylglycerol, on proteins that impinge on insulin-derived signals. Mixtures of FFAs arterially injected *in vivo* induced the activation of protein kinase C (PKC)-Θ or JNK in skeletal muscle.[@b11-dmso-3-173],[@b17-dmso-3-173],[@b52-dmso-3-173] PKC-Θ, like JNK, can inactivate IRS-1 and its downstream signaling towards metabolic outcomes.[@b52-dmso-3-173] This is achieved by distinct serine phosphorylation of IRS-1 that reduces the signal-bearing tyrosine phosphorylation.[@b29-dmso-3-173] In contrast, saturated FFAs act largely to produce ceramides that spare IRS-1 but still inhibit insulin action downstream, at the level of the serine/threonine kinase Akt to also inhibit metabolic outcomes.[@b54-dmso-3-173],[@b55-dmso-3-173] Interestingly, direct exposure of insulin-target cells to cytokines such as TNF-α and IL-1β also activates JNK and IKK,[@b56-dmso-3-173] making these factors a common link in the molecular mechanism of lipotoxicity and inflammation leading to insulin resistance and T2DM via post-transcriptional actions.[@b53-dmso-3-173] Indeed, heterozygous deletion in IKKβ (ie, in IKKβ^+/−^ mice) improved insulin sensitivity in obese mice target cells.[@b57-dmso-3-173] In addition, TNF-α upregulates the expression of suppressor of cytokine signaling (SOCS) proteins, which bind to IRS-1 to mediate its degradation.[@b58-dmso-3-173] Furthermore, cytokine-mediated transcriptional up-regulation of JNK and IKK increases the expression of AP-1 and NFκB[@b59-dmso-3-173] that, in turn, activate TNF-α to further propagate local and systemic inflammatory responses.[@b60-dmso-3-173] Hence, JNK--AP-1 and IKK--NFκB are the major inflammatory pathways that disrupt insulin signaling *via* a series of transcriptional events and can be potentially modulated to improve insulin sensitivity and glucose homeostasis.[@b17-dmso-3-173]

An additional and highly relevant interaction between lipids and inflammation is the recent discovery that FFAs can directly activate macrophages to produce cytokines that render muscle cells insulin resistant.[@b11-dmso-3-173],[@b61-dmso-3-173] Such studies in cell culture are proof of principle that elevated FFAs can activate cells of the innate immune system to provoke muscle cell insulin resistance. In this case, both the macrophages and muscle cells showed activated JNK and IKK.

Inflammatory network: Biomarkers of T2DM
----------------------------------------

It is estimated that up to 25% of patients with newly diagnosed T2DM already present evidence of systemic inflammation at the time of diagnosis,[@b62-dmso-3-173] suggesting that the disease (or the hypertriglyceridemia) has been present already for years since the development of status that predisposes to the disease (eg, overweight; see [Figure 2](#f2-dmso-3-173){ref-type="fig"}).[@b63-dmso-3-173]--[@b65-dmso-3-173] Current approaches to diabetes screening include determination of an elevated fasting plasma glucose level (≥126 mg/dL, ie, 7.0 mmol/L) on two occasions, or an oral glucose tolerance test (OGTT) yielding ≥200 mg/dL (11.1 mmol/L) after 2 h, or symptoms of uncontrolled diabetes with a random plasma glucose level ≥200 mg/dL (11.1 mmol/L). In addition, a score of glycosylated hemoglobin levels above 7% (HbA~1c~ ≥0.07) has been suggested as evidence of disease.[@b4-dmso-3-173] None of these techniques has been found to detect all incident cases of T2DM and there is still a need to establish more sensitive and specific predictors of early risk.[@b66-dmso-3-173] Although inherited dysfunction in insulin signaling plays a role in the risk of T2DM, it is likely that any genetic component will be modified by environmental factors. Capturing the contribution of these genetic factors and their interaction with environmental covariates (eg, diet, physical activity, etc.) in the development of T2DM may provide an effective approaches for early detection and prevention.[@b66-dmso-3-173],[@b67-dmso-3-173]

Inherited variations such as SNPs or CNVs in genes encoding for innate immunity-related inflammation may play a pivotal role in the susceptibility to T2DM and an array of chronic diseases.[@b68-dmso-3-173]--[@b72-dmso-3-173] Genetic polymorphisms, in conjunction with various environmental factors, may affect serum levels of cytokines and inflammatory markers and the subsequent risk of T2DM[@b68-dmso-3-173]--[@b71-dmso-3-173] (see [Table 1](#t1-dmso-3-173){ref-type="table"}). Identification of SNPs or CNVs of inflammation-related genes, their frequencies and their association with risk of T2DM will assist in defining the genetic basis of the disease and early detection of risk.

The feasibility of utilizing inflammatory markers in screening T2DM risk can be substantiated from numerous experimental, clinical and epidemiological observations demonstrating: a) the ability of inflammatory factors to predict the disease independently from established risk factors, [@b73-dmso-3-173]--[@b76-dmso-3-173] b) their link to one another by virtue of their common action, and c) the availability of quantitative, lessinvasive methods of assay, that would allow for repeated measurements. These characteristics render inflammatory mediators as potential candidates for a panel of powerful biomarkers for predicting T2DM incidence. As indicated in [Figure 2](#f2-dmso-3-173){ref-type="fig"}, overweight sets the stage for low-grade chronic inflammation, with adiponectin levels decreasing while resistin, FFAs and TNF-α increase. As overweight progresses to obesity, continued inflammation further leads to elevated CRP, fibrinogen, IL-6, IL-1β and haptoglobin. Obesity can be complicated by metabolic dysregulation (metabolic syndrome) to develop frank T2DM where LDL-cholesterol and triglyceride levels increase, HDL-cholesterol levels deceases and hypertension and IGT manifest.[@b9-dmso-3-173],[@b29-dmso-3-173],[@b30-dmso-3-173],[@b65-dmso-3-173],[@b66-dmso-3-173],[@b77-dmso-3-173] Throughout the pathologic continuum from overweight to T2DM, insulin resistance increases progressively and the risk of cardiovascular disease (CVD) elevates. Metabolic syndrome is associated with about twofold increased susceptibility to CVD whereas T2DM is linked to fourfold higher risk.[@b63-dmso-3-173],[@b64-dmso-3-173] Public health initiatives aimed at preventing and controlling T2DM should be targeted towards the early stages of the disease, to prevent obesity and the cascade of inflammatory events that eventually leads to the clinical manifestation of T2DM. We next discuss the characteristics of cytokines and chemokines with potential to become biomarkers of inflammation and insulin resistance associated with obesity, ie, early T2DM risk detection.

TNF-α
-----

TNF-α is a primary mediator of many of the systemic acute responses related to severe infections with gramnegative bacteria.[@b78-dmso-3-173] The major cellular source of TNF-α is activated mononuclear phagocytes, antigen-stimulated T-cells, natural killer (NK) cells, and mast cells. The *TNF-α*gene is constitutively expressed in adipose tissue, where it originates principally from macrophage infiltration rather than from the adipocytes themselves.[@b16-dmso-3-173] In adipose tissue from obese subjects, TNF-α mRNA expression is 2.5-fold higher than in lean subjects and is strongly correlated with hyperinsulinemia.[@b26-dmso-3-173] Body weight reduction in obese people[@b26-dmso-3-173] and *in vivo* TNF-α inhibition[@b16-dmso-3-173] significantly reduced serum TNF-α and improved insulin sensitivity. High TNF-α is related to the pathophysiology of insulin resistance and T2DM,[@b45-dmso-3-173] possibly through its impact on IRS-1 as discussed above,[@b16-dmso-3-173],[@b26-dmso-3-173],[@b58-dmso-3-173],[@b79-dmso-3-173] or by enhancing the apoptosis of pancreatic β-cells.[@b80-dmso-3-173]

The association of the *TNF-α* gene polymorphisms with T2DM has been extensively investigated but with conflicting results. Some studies demonstrate a strong association between *TNF-α* SNPs and T2DM[@b81-dmso-3-173]--[@b83-dmso-3-173] ([Table 1](#t1-dmso-3-173){ref-type="table"}) whereas others show no relationship.[@b84-dmso-3-173],[@b85-dmso-3-173] Although a number of variants have been identified in the *TNF-α* gene, the functional SNPs rs361525 (−238 G\>A) and rs1800629 (−308 G\>A) were identified in the promoter region. The functionality of the variant −308A allele is related to a twofold increase in transcriptional activity compared to the wild-type allele.[@b86-dmso-3-173] Interestingly, this variant was suggested to play a critical role in the genetic predisposition to excessive fat accumulation in women in early stages of obesity,[@b82-dmso-3-173] and to predict the conversion from IGT to T2DM.[@b81-dmso-3-173] The rs1800629 SNP exhibited a gene--gene interaction effect with the *IL-6* rs1800795 (−174 C\>G) in the early risk prediction of T2DM.[@b81-dmso-3-173] On the other hand, the rs361525 is located in a repressor site of the promoter, a 10 bp sequence with homology to the binding site of the activator protein AP-2 regulating TNF-α function. [@b87-dmso-3-173] Another SNP in TNF-α which was recently reported to be associated with increased risk of T2DM, is rs1800610 (IVS1+123 G\>A).[@b83-dmso-3-173] The functional relevance of this SNP pertains to the YY1 transcription factor that binds specifically to the intron 1 region where the rs1800610 resides and evokes increased TNF-α expression.[@b83-dmso-3-173]

IL-6
----

IL-6 is produced by many cell types including fibroblasts, endothelial cells, and monocytes-macrophages.[@b88-dmso-3-173],[@b89-dmso-3-173] However, a significant proportion of the circulating IL-6 (15%--30%) rep., repeats; TNFα, tumor necrosis factor-α; T2DM, type 2 diabetes mellitus. derives from adipose tissue production in the absence of acute inflammation[@b90-dmso-3-173] to modulate adipocyte glucose and lipid metabolism.[@b91-dmso-3-173],[@b92-dmso-3-173] In obesity, IL-6 synthesis is upregulated in adipocytes[@b88-dmso-3-173],[@b93-dmso-3-173] and correlates with circulating IL-6[@b94-dmso-3-173] and with the extent of insulin resistance.[@b77-dmso-3-173],[@b93-dmso-3-173],[@b95-dmso-3-173] IL-6 also triggers the hepatic synthesis of CRP and correlates with its serum levels. [@b94-dmso-3-173],[@b95-dmso-3-173] Additionally, IL-6 promotes hepatic VLDL secretion and hypertriglyceridemia.[@b27-dmso-3-173],[@b96-dmso-3-173] These observations suggest a link between IL-6 levels, obesity and inflammation in the pathogenesis of T2DM[@b97-dmso-3-173] and demonstrate that IL-6 can be considered as a candidate biomarker for early T2DM risk detection.

Several mechanisms have been proposed to explain how IL-6 can mediate insulin resistance.[@b17-dmso-3-173],[@b56-dmso-3-173],[@b77-dmso-3-173],[@b93-dmso-3-173],[@b95-dmso-3-173],[@b98-dmso-3-173] The IL-6 receptor (IL6R) belongs to the cytokine class I receptor family that includes the JNK signal transduction pathway.[@b53-dmso-3-173],[@b99-dmso-3-173] JNK activation by IL-6 induces STAT (signal transducers and activators of transcription) phosphorylation, dimerization, and translocation to the nucleus to regulate the transcription and function of an array of target genes including *IRS, AP-1*, and *NFκB*[@b53-dmso-3-173],[@b59-dmso-3-173] in hepatocytes and adipocytes.[@b100-dmso-3-173] Transcriptional upregulation of these genes promotes both localized and systemic inflammatory responses[@b60-dmso-3-173] to mediate fatty liver and insulin resistance.[@b101-dmso-3-173] The interaction between IL-6 and the insulin pathway also involves mediating the interaction between SOCS proteins and the INSR.[@b102-dmso-3-173]--[@b104-dmso-3-173] Therefore, IL-6 antagonists and factors that target JNK and IKK may offer promising preventive and/or therapeutic approaches to improve insulin sensitivity.[@b32-dmso-3-173],[@b105-dmso-3-173]

In humans, numerous studies have demonstrated that elevated levels of IL-6 are associated with an increased incidence of T2DM independent of obesity[@b73-dmso-3-173]--[@b76-dmso-3-173] or fasting insulin levels.[@b74-dmso-3-173] The relative risk of the disease for individuals with IL-6 levels in the highest tertile (vs lowest tertile) was 2.02 (95% confidence interval \[CI\]: 1.14--3.58), after adjustment for BMI, lifestyle factors, and pre-existing CVD.[@b73-dmso-3-173] Furthermore, chronically elevated IL-6 was related to a range of metabolic abnormalities typical of an insulin resistant state.[@b97-dmso-3-173] Several polymorphisms exist in the *IL-6* and *IL6R* ([Table 1](#t1-dmso-3-173){ref-type="table"}). Two common SNPs in the promoter region of *IL-6*, rs1800795 (−174 G\>C) and rs1800796 (−572 G\>C) were examined for their role in predisposition to T2DM. These SNPs were investigated in a large meta-analysis of \>20,000 participants from 21 published and unpublished studies for their association with T2DM.[@b106-dmso-3-173] The allele −174C was associated with reducing the risk of T2DM by nearly 10% (odds ratio \[OR\] = 0.91; *P* \< 0.037) and exhibited a gene--gene interaction with the *TNF-α* rs1800629 in predicting disease risk.[@b81-dmso-3-173] No evidence for association was found, however, between rs1800796 and T2DM.[@b106-dmso-3-173] Overall, these findings, although indicative of a role for IL-6 polymorphisms in T2DM, suggest that additional studies are needed to confirm this association, particularly in relation to other genes along the innate immunity and inflammatory pathways. Moreover, studies that examine gene--environment interactions may yield more meaningful results and provide important insights into the role of IL-6 in the pathogenesis of T2DM as well as its value as a biomarker of early disease risk detection.

CRP
---

CRP is an acute-phase reactant produced primarily in the liver under the stimulation of adipocyte-derived IL-6 and TNF-α. It exhibits several characteristics that imply a fundamental immunoregulatory function. Specifically, CRP is a member of the pentraxin family of oligomeric proteins involved in PRRs activation. CRP also enhances leukocyte reactivity, complement fixation, modulation of platelet activation, and clearance of cellular debris from sites of active inflammation. [@b50-dmso-3-173],[@b107-dmso-3-173] The magnitude and rapidity of its induction and its cooperative role in innate immune response, as well as its ease of measurement, all make CRP a common marker for inflammation.[@b108-dmso-3-173] Furthermore, CRP is invariably correlated with various parameters relevant to diabetes, including obesity, lipogenesis, and adiponectin.[@b66-dmso-3-173] In this respect, CRP was shown to be consistently associated with the incidence of T2DM in populations of otherwise healthy persons.[@b66-dmso-3-173],[@b109-dmso-3-173] A recent study estimated that one-third of T2DM cases can be associated with elevated serum CRP.[@b109-dmso-3-173] Although the relationship between CRP and T2DM was thought to be stronger in women than men,[@b42-dmso-3-173] subjects of both sexes with high serum CRP (\>2.6 mg/L) had more than double the overall T2DM risk (OR = 2.37; 95% CI: 1.57--3.58) compared to those with levels of \<0.5 mg/L.[@b109-dmso-3-173] Together, these findings substantiate a role for CRP as a possible candidate biomarker for early T2DM risk detection.

Numerous prospective studies demonstrate an independent positive association of CRP with the presence of T2DM[@b38-dmso-3-173],[@b75-dmso-3-173],[@b76-dmso-3-173],[@b109-dmso-3-173]--[@b114-dmso-3-173] while others show no association after adjustment for adiposity and insulin resistance.[@b39-dmso-3-173],[@b41-dmso-3-173],[@b74-dmso-3-173],[@b115-dmso-3-173] A meta-analysis of available data from 10 prospective studies showed a positive association between serum CRP and T2DM independent of obesity.[@b109-dmso-3-173] Another meta-analysis of 16 published studies with 3,920 T2DM cases and 24,914 controls demonstrated a relative risk (RR) of T2DM of 1.72 (95% CI: 1.54--1.92) for subjects with high CRP levels.[@b116-dmso-3-173] A major mechanism by which CRP plays a critical role in T2DM is primarily by its action on pancreatic β-cell.[@b117-dmso-3-173],[@b118-dmso-3-173] For example, CRP significantly inhibits cell proliferation and increases the rates of apoptotic cell death.[@b119-dmso-3-173] This effect was connected to the CRP-mediated modulation of protein kinase B (PKB), a key factor for cell survival pathways and to its ability to induce the production of TNF-α, IL-1β and matrix metalloproteinase-9 (MMP-9) in a concentration-dependent manner.[@b119-dmso-3-173]

Several SNPs were identified in the *CRP* gene and were linked to elevated levels of serum CRP,[@b120-dmso-3-173] low insulin sensitivity,[@b121-dmso-3-173] and incidence of T2DM.[@b122-dmso-3-173]--[@b124-dmso-3-173] Among these SNPs, the variants rs3093059 (−757 A\>G)[@b120-dmso-3-173],[@b121-dmso-3-173],[@b123-dmso-3-173] and rs2794521 (−717 A\>G)[@b120-dmso-3-173]--[@b123-dmso-3-173] were extensively studied and were reported to be associated with an increased risk of T2DM. Furthermore, CRP SNPs at the 3' end--rs1800947 (1059 G\>C) and rs1130864 (1444 C\>T)--were associated with decreased and increased concentrations of CRP, respectively.[@b125-dmso-3-173] Several studies demonstrate that serum CRP can be additively influenced by the *IL-6*--*CRP* gene--gene interaction.[@b126-dmso-3-173]--[@b129-dmso-3-173] Increased serum CRP in obese individuals was correlated with elevated secretion of IL-6 and TNF-α in adipocytes and predisposes to the chronic inflammatory state associated with T2DM.[@b21-dmso-3-173]

Overall, evaluating the effect of inflammatory factors in T2DM may provide new public health approaches for disease prevention and a novel strategy for early detection. These markers are evidently related to risk of T2DM and can be employed in early detection of disease risk and as a predictive measure of response to preventive intervention. If the extent of interaction between the genetic (eg, polymorphisms in *TNF-α*, *IL-6*, and *CRP* genes), biochemical (eg, serum levels of TNF-α, IL-6, and CRP), and environmental (eg, micronutrient supplementation) factors and the risk of T2DM can be established, a selected set of innate immunity-related inflammatory markers could become a powerful panel of integrated multiplex biomarkers for the early risk detection of T2DM. This integration may permit maximizing the sensitivity, specificity, and predictability of biomarkers to T2DM in the general population. A set of inflammatory markers could be utilized to develop effective and novel strategies for disease intervention based on supplementation with micronutrients that modify (ie, lower) their gene expression or serum levels (see below).

Attenuating inflammatory response in T2DM by micronutrients
-----------------------------------------------------------

Factors that attenuate inflammation (and the inflammatory markers proposed above, such as TNFα, IL-6, and CRP) could provide an important public health tool to reduce the burden of diseases related to this pathway, such as obesity, T2DM and cardiovascular diseases, in the general population. The feasibility of modulating innate immunity-related inflammation as an approach for the prevention of T2DM is based on reports that evaluated the efficacy of anti- inflammatory pharmaceutical agents on disease manifestation and outcome. [@b14-dmso-3-173],[@b32-dmso-3-173],[@b105-dmso-3-173]

The major current therapeutic agents to treat T2DM, sulfonylureas, metformin, and insulin-sensitizing glitazones, all improve metabolic control and lead to normalization of circulating inflammation markers through, at least partly, interaction with the innate immunity-related pathway. Sulfonylureas increase insulin release from pancreatic β-cells,[@b130-dmso-3-173] whereas metformin suppresses glucose production in the liver and increases insulin sensitivity in peripheral tissues.[@b131-dmso-3-173] Glitazones bind to peroxisome proliferator-activated receptors (PPARs), initiating transcriptional activity that leads to improved insulin action.[@b132-dmso-3-173] While not necessarily acting primarily to reduce inflammation, it is likely that these drugs' correction of glucose and insulin levels impinges on the innate immune system, attenuates inflammation and further improves insulin action. Accordingly, glitazones reduced serum levels of CRP (30% reduction in 1 week), PAI-1, TNF-α and other inflammatory markers.[@b7-dmso-3-173],[@b133-dmso-3-173] Statins, metformin and sulfonylureas have comparable anti-inflammatory activity.[@b8-dmso-3-173],[@b9-dmso-3-173],[@b134-dmso-3-173]

A therapeutic strategy for T2DM that would act primary on the inflammatory system has been proposed in the form of salicylates, an anti-inflammatory agent that inhibits IKK[@b135-dmso-3-173] and is long known to have a hypoglycemic effect.[@b136-dmso-3-173],[@b137-dmso-3-173] Nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase inhibitors are able to enhance glucose-induced insulin release, improve glucose tolerance, and increase the effect of insulin in patients with T2DM.[@b17-dmso-3-173],[@b29-dmso-3-173],[@b105-dmso-3-173] In humans, treatment with NSAIDs improved various biochemical indices associated with T2DM ([Table 2](#t2-dmso-3-173){ref-type="table"}). Although these observations support the notion that inflammation plays a pivotal role in T2DM, attenuating inflammation as a strategy for disease prevention in a public health setting will necessitate a substantially different perspective. In this case, a strategy that can be introduced into the general population with the least (if any) side effects and the maximal preventive outcome should be adopted. In this context, a nutritional intervention approach would be a desirable option.

In general, studies in animal models and humans have demonstrated that disrupting the IKKβ-NFκB pathway improves obesity-related insulin sensitivity.[@b14-dmso-3-173] Furthermore, blocking JNK activity in animal models of diabetes enhanced systemic glucose homeostasis and insulin sensitivity,[@b32-dmso-3-173] whereas inhibition of IKK by salicylates led to an overall improved insulin action.[@b105-dmso-3-173]

Micronutrient, certain fatty acids (eg, omega-3 fatty acid) and/or trace element supplementation can modify innate immune-related responses and, subsequently, modify the risk of a range of chronic conditions. With respect to T2DM, the consensus of available information suggests that micronutrient intake modulates the innate immune system[@b138-dmso-3-173] and can subsequently influence the predisposition to (and prevention of) disease.[@b80-dmso-3-173],[@b138-dmso-3-173],[@b139-dmso-3-173] By virtue of this observation, the hope is that the outcome of nutritional supplementation can be simply monitored via its modifying action on the levels of inflammatory biomarkers. Many micronutrients exhibit well-characterized anti-inflammatory or immunomodulatory functions (see below). Vitamins (eg, D, E, and C), certain fatty acids (eg, omega-3 fatty acid) and trace elements (eg, selenium, zinc, copper and iron) are known to improve the overall function of the immune system, prevent excessive expression and synthesis of inflammatory cytokines, and increase the 'oxidative burst' potential of macrophages.[@b138-dmso-3-173] Natural health products (NHPs) that contain pertinent micronutrients (eg, so-called adaptogenic medicinal plants) or modulate the innate immune system on their own (eg, omega-3 fatty acids and probiotics) also represent an interesting avenue to study, although the evidence base for their beneficial action is highly variable.[@b140-dmso-3-173] Exploring the possibility that supplementation with selected micronutrients, trace elements and/or other NHPs can attenuate obesityrelated inflammation in order to delay the development of T2DM should be considered alongside existing public health practices to reduce the rising incidence of the disease.

Vitamin D
---------

Vitamin D insufficiency has been associated with a wide range of chronic diseases, including autoimmune diseases, atherosclerosis, cancer, obesity, cardiovascular diseases, and diabetes.[@b141-dmso-3-173] In T2DM, the role of vitamin D was suggested from the presence of vitamin D receptors (VDR) in the pancreatic β-islet cells.[@b142-dmso-3-173] In these cells, the biologically active metabolite of vitamin D (ie, 1,25-dihydroxy-vitamin D; 1,25(OH)D)[@b138-dmso-3-173] enhances insulin production and secretion via its action on the VDR.[@b142-dmso-3-173] Indeed, the presence of vitamin D-binding protein (DBP), the principal predictor of serum levels of 25(OH)D and response to vitamin D supplementation, [@b143-dmso-3-173] and VDR initiated several studies demonstrating a relationship between SNPs in the genes regulating *VDR* and *DBP* with glucose intolerance and insulin secretion.[@b144-dmso-3-173]--[@b146-dmso-3-173] This further supports a role of vitamin D in T2DM and may explain the reduced overall risk of T2DM in subjects who ingest \>800 IU/d of vitamin D.[@b80-dmso-3-173],[@b139-dmso-3-173] However, an alternative, and perhaps related, explanation was recently proposed based on the potent immunomodulatory functions of vitamin D.[@b147-dmso-3-173]--[@b149-dmso-3-173] VDRs are present in most types of immune cells[@b150-dmso-3-173] and 1,25(OH)D modulates the production of the immunostimulatory IL-12 and the immunosuppressive IL-10.[@b151-dmso-3-173] In this respect, supplementation with vitamin D[@b33-dmso-3-173] or its bioactive form 1,25(OH)D[@b138-dmso-3-173] improved insulin sensitivity by preventing the excessive synthesis of inflammatory cytokines. This effect on cytokine synthesis is due to its interaction with vitamin D response elements (VDRE) present in the promoter region of cytokine-encoding genes. This interaction downregulates the transcriptional activities of cytokine genes and attenuates the synthesis of the corresponding proteins.[@b33-dmso-3-173] Vitamin D also deactivates NFκB that transcriptionally regulates the pro-inflammatory cytokineencoding genes.[@b152-dmso-3-173] Downregulating the expression of NFκB and downstream cytokine genes inhibits β-cell apoptosis and promotes their survival.[@b33-dmso-3-173] Numerous intervention trials, clinical studies, and epidemiological findings demonstrated that supplementation with vitamin D can be beneficial in optimizing processes linked to T2DM such as insulin response, and hence, may markedly improve T2DM prevention strategies. [@b80-dmso-3-173],[@b142-dmso-3-173] For example, increasing intake of vitamin D to \>800 IU daily, along with 1200 mg of calcium, reduced the risk of developing T2DM by 33%.[@b80-dmso-3-173] In agreement, healthy older adults with impaired fasting glucose showed significant improvement in glycemic and insulin responses when they increased their intake of vitamin D by 700 IU/day and calcium by 500 mg/day for three years.[@b139-dmso-3-173] Therefore, exploring the possibility that vitamin D can modify the action of innate immunity genes to attenuate the T2DM-associated lowgrade chronic inflammatory response, and prevent disease development and/or progression, may represent an attractive approach for public health intervention, both in the general population as well as in vulnerable subpopulations. It should however, be considered that vitamin D serum levels, and subsequently extent of supplementation, will vary considerably depending on sunlight exposure; an observation that should be taken into account when employing it in public health intervention of T2DM.

Vitamin E
---------

Vitamin E is known to have a significant impact on improving a variety of immune functions.[@b153-dmso-3-173] Supplementation with vitamin E increases the rate of lymphocyte proliferation by enhancing the ability of T cells to undergo cell division cycles.[@b154-dmso-3-173] The effective anti-inflammatory action of vitamin E was substantiated from observations such as the increased expression of the IL-2 gene and IL-1 receptor antagonist and the decreased expression of IL-4 following vitamin E supplementation in animal models.[@b153-dmso-3-173] Furthermore, vitamin E reduced the serum levels of IL-1β, IL-6, TNF-α, PAI-1, and CRP in T2DM patients.[@b155-dmso-3-173] These anti-inflammatory actions are thought to result from its inhibitory effect on the 5-lipoxygenase (5-LOX) at the post-transcriptional level.[@b156-dmso-3-173] 5-LOX is a member of the lipoxygenase family of enzymes involved in the synthesis of the inflammatory prostaglandins. Additional anti-inflammatory functions of vitamin E include its downregulation of NFκB[@b155-dmso-3-173] and its potent lipophilic antioxidant effect on internal and external cell membranes as well as plasma lipoproteins, notably LDL. Based on this latter characteristic, studies in both animal models and humans have demonstrated that vitamin E intake blocks LDL lipid peroxidation, prevents the oxidative stress linked to T2DMassociated abnormal metabolic patterns (hyperglycemia, dyslipidemia, and elevated levels of FFAs), and, subsequently, attenuates cytokine gene expression.[@b153-dmso-3-173],[@b155-dmso-3-173],[@b157-dmso-3-173],[@b158-dmso-3-173] Despite these findings, a recent study evaluated the effects of a combination of vitamin C (1000 mg/day) and vitamin E (400 IU/day) for four weeks on insulin sensitivity in untrained and trained healthy young men and concluded that such supplementation may preclude the exercise-induced amelioration of insulin resistance in humans.[@b159-dmso-3-173] This may relate to the source of vitamin E used, ie, α-, β- γ-, or δ-tocopherol.[@b160-dmso-3-173] Nevertheless, in general, the immunomodulatory, anti-inflammatory and anti-oxidative functions of vitamin E strongly support its possible application in designing effective prevention and/or treatment protocols for T2DM.[@b157-dmso-3-173]

Current practices for diabetes prevention in the general population include lifestyle change, dietary intervention and exercise. As suggested above, micronutrient supplementation may aid in T2DM prevention and control through the anti-oxidant, anti-inflammatory and immunomodulatory properties of various vitamins and trace elements. It seems reasonable, therefore, to suggest that the two preventive approaches for T2DM (ie, micronutrient supplementation and lifestyle change) may be combined into a single program to enhance the success and effectiveness of intervention. This strategy could be more efficient in reducing the low-grade inflammation associated with pre-clinical T2DM and, subsequently the disease burden, than when a single approach is considered. Moreover, such a combined strategy can be introduced in general practice settings and in a population-based fashion with low expenditure and minimal side effects.

Conclusions
===========

The current state of knowledge warrants further study into the extent of association between inflammatory markers and early stages of T2DM, on one hand, and the effect of micronutrients in modifying this relationship, on the other. Such an approach is critical to comprehensively evaluate the prospect of applying inflammatory network assessment in disease surveillance. A significant public health potential of developing this set of evidence-based biomarkers can be conceptualized from their application as precise genomic-based measures of risk prediction for T2DM beyond the simple risk factors presently employed, such as family history or physical examination. In this respect, inflammatory biomarkers may permit capturing the etiological function of (and interaction between) genetic constitution and environmental risk modifiers in the T2DM pathogenesis. Furthermore, a major benefit of introducing inflammatory markers into public health settings stems from their potential to facilitate developing a novel class of agents which attenuate low-grade inflammation prior to the clinical onset of T2DM and to be employed in disease prevention. However, before applying these biomarkers in public health, protocols for their assessment should be standardized and laboratory reference intervals need to be used in decision-making processes.

Employing this set of biomarkers in evaluating responses to prevention may necessitate examining the contribution of dynamic interaction between genetic and dietary modifiers in the etiology of T2DM, as well as the influence of these factors on inflammation at the early disease stages. It seems likely that micronutrient supplementation can modify the genotype--phenotype association within the innate immune response. This proposition may elucidate the mechanisms by which nutritional factors prevent or delay disease development and can be introduced into the general population and susceptible subpopulations. The efficacy of micronutrient supplementation to attenuate or balance the innate immune response and the ensuing inflammation first needs to be further explored and optimized; in some cases, this includes developing tools to accurately and reproducibly measure the circulating/tissue levels of potential biomarkers in order to relate it to clinical outcome. The impact of micronutrients on T2DM incidence may then be assessed through a series of pilot population-based studies: firstly, to determine the feasibility and effectiveness of this protocol; second, to validate and evaluate the strategy and ensure replication of results; and, third, to monitor the outcome to quantify the overall preventive response in comparison (and combination) with the current preventive approaches for T2DM such as lifestyle changes, exercise, and dietary intervention.
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![The interaction between insulin signaling and fatty acids in the synthesis of pro-inflammatory cytokines and inflammatory markers.\
**Notes:** Current information suggests that insulin activates INSR to stimulate the phosphorylation of multiple tyrosine residues in the IRS and promote diverse biological responses. Illustrated here is the response of stimulation of glucose transport into muscle and fat cells. Activation of TLR4 by fatty acids initiates intracytoplasmic signals that activate the JNK--AP-1 and IKK--NFκB axes which in turn increase the expression of cytokine-encoding genes. Cytokines initiate the hepatic production of APPs (eg, CRP, fibrinogen, haptoglobin, etc.) and dysregulate the INSR-IRS-mediated glucose transport into promoting serine phosphorylation of IRS that in turn reduces its tyrosine phosphorylation and, thereby, disrupts the insulin action.\
**Abbreviations:** AKT, protein kinases B (PKB); AP-1, activator protein-1; APPs, acute phase proteins; G, glucose; GLUT4, glucose tansporter-4; I, insulin; IKK, inhibitor of NFκB kinase-β; IL-1β and -6, interleukin-1 β and -6; INSR, insulin receptor; IRAK1 and 4, interleukin-1 receptor-associated kinase 1 and 4; IRS, insulin substrate; JNK, c-Jun amino-terminal kinase; MyD88, myeloid differentiation primary response gene-88; NFκB, nuclear factor κ B; PI3K, phosphoinositide-3 kinase. PI(3,4,5)P3, Phosphatidylinositol 3,4,5-trisphosphate. PKC, protein kinase C. TAB, TAK binding protein. TAK1, mitogen-activated protein kinase kinase kinase (MAPKKK). TLR4, toll-like receptor-4; TNFα, tumor necrosis factor-α; TRAF6, TNF receptor-associated factor 6.](dmso-3-173f1){#f1-dmso-3-173}

![The relationship of inflammatory markers and disease factors to specific stages pathologic continuum from overweight to T2DM and cardiovascular diseases.[@b63-dmso-3-173],[@b64-dmso-3-173]\
**Note:** Depicted are the increases or decreases (see text) in relative values of various inflammatory markers and disease factors that take place as overweight progresses towards T2DM.\
**Abbreviations:** CRP, C-reactive protein; FFA, free fatty acids; IGT, impaired glucose tolerance; IL, interleukin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; T2DM, type 2 diabetes mellitus.](dmso-3-173f2){#f2-dmso-3-173}

###### 

Selected pro-inflammatory cytokine gene polymorphisms positively associated with T2DM and related risk factors and clinical complications[@b68-dmso-3-173]--[@b72-dmso-3-173][a](#tfn1-dmso-3-173){ref-type="table-fn"}

  Condition^b^           SNP
  ---------------------- -------------------------------------------------------------
  BMI                    IL-6 -174C\>G, IL6 CA rep., TNFα -308G\>A
  IGT                    IL-6 -174C\>G
  Insulin resistance     IL-6 -174C\>G, TNFα -308G\>A
  Obesity                IL-6 -174C\>G, IL6R 394T\>G, TNFα -308G\>A
  T2DM                   IL-6 -174C\>G, IL6R 48867A\>G, TNFα -308G\>A, TNFα -863C\>A
  Diabetic nephropathy   IL-6 -634C\>G, IL1β--511C\>T

**Note:** A selected list of SNPs positively linked to T2DM and related conditions was presented.

**Abbreviations:** BMI, body mass index; IGT, impaired glucose tolerance; IL, interleukin.

###### 

Effect of attenuating inflammation by anti-inflammatory factors on biochemical measures of predisposition to T2DM[@b105-dmso-3-173][a](#tfn3-dmso-3-173){ref-type="table-fn"}

  Characteristic                                 Effect[b](#tfn4-dmso-3-173){ref-type="table-fn"}   \% Change[c](#tfn5-dmso-3-173){ref-type="table-fn"}
  ---------------------------------------------- -------------------------------------------------- -----------------------------------------------------
  Fasting plasma glucose                         ↓                                                  25
  Basel hepatic glucose production               ↓                                                  20
  Glucose uptake                                 ↑                                                  20
  Insulin-stimulated peripheral glucose uptake   ↑                                                  20
  Insulin clearance                              ↓                                                  30
  Total cholesterol                              ↓                                                  15
  Fatty acid levels                              ↓                                                  50
  Triglycerides                                  ↓                                                  50
  CRP                                            ↓                                                  15

**Notes:** Subjects with T2DM (*n =* 9) were treated with high-dose aspirin (\~7 g/day divided in 5 equal doses) for two weeks;

Effect is shown as decrease (↓) or increase (↑);

Changes represent the difference in biochemical measures (%) before and after treatment.

**Abbreviations:** CRP, C-reactive protein; T2DM, type 2 diabetes mellitus.
